Boston Family Office LLC Acquires 473 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Boston Family Office LLC boosted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 27,381 shares of the company’s stock after purchasing an additional 473 shares during the quarter. Boston Family Office LLC’s holdings in IDEXX Laboratories were worth $11,320,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. FSA Wealth Management LLC purchased a new stake in IDEXX Laboratories during the 3rd quarter valued at approximately $25,000. Rialto Wealth Management LLC bought a new position in shares of IDEXX Laboratories during the fourth quarter worth $30,000. Retirement Wealth Solutions LLC purchased a new position in IDEXX Laboratories during the fourth quarter valued at $31,000. Kestra Investment Management LLC bought a new stake in IDEXX Laboratories in the 4th quarter valued at $38,000. Finally, Crews Bank & Trust bought a new stake in IDEXX Laboratories in the 4th quarter valued at $41,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Up 1.0 %

NASDAQ IDXX opened at $419.95 on Tuesday. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $548.88. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The company has a fifty day moving average of $437.08 and a two-hundred day moving average of $442.03. The firm has a market capitalization of $34.04 billion, a price-to-earnings ratio of 39.36, a PEG ratio of 3.41 and a beta of 1.39.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on IDXX. Leerink Partners assumed coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price objective for the company. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Morgan Stanley reduced their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Barclays upped their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Finally, Bank of America raised their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $533.75.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at $3,781,645.28. This represents a 54.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. The trade was a 49.50 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.